Mechanism of TIPS to Improve Sarcopenia
Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
132 participants
Jun 1, 2025
OBSERVATIONAL
Conditions
Summary
Sarcopenia is particularly common in patients with chronic liver disease, especially in patients with decompensated cirrhosis, where the prevalence can be more than 50%. Sarcopenia is an important risk factor for a significant increase in mortality in cirrhotic patients, and is closely associated with a high incidence of complications such as hepatic encephalopathy, ascites, and infections . Recent studies have found that TIPS not only significantly improves clinical symptoms caused by portal hypertension, but may also have a positive effect on skeletal muscle mass and function in patients. Although the effect of TIPS in improving sarcopenia has been preliminarily confirmed, its mechanism is not yet fully understood. Therefore, there is an urgent need to explore the mechanism of action of TIPS to improve sarcopenia and provide guidance for clinical treatment options.
Eligibility
Inclusion Criteria3
- Diagnosed with liver cirrhosis and needing TIPS surgical treatment;
- Aged between 18-80 years old;
- Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits.
Exclusion Criteria5
- Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.);
- Suffering from malignant tumors and in the active stage;
- Recent (within 3 months) history of major surgeries or traumas;
- The presence of mental illness or cognitive disorders, which are unable to cooperate with the study;
- Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06794853